Selexipag: still looking for its place
- PMID: 39362684
- DOI: 10.1183/13993003.01560-2024
Selexipag: still looking for its place
Conflict of interest statement
Conflicts of interest: M.M. Hoeper reports honoraria for speaking, steering committees, or scientific advisory boards from Acceleron, Actelion, AOP Health, Bayer, Ferrer, Gossamer Bio, Inhibikase Therapeutics, Janssen, Keros, MSD and Novartis.
Comment on
-
Efficacy and safety of selexipag in patients with inoperable or persistent/recurrent CTEPH (SELECT randomised trial).Eur Respir J. 2024 Oct 3;64(4):2400193. doi: 10.1183/13993003.00193-2024. Print 2024 Oct. Eur Respir J. 2024. PMID: 39326918 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources